- An extensive panel of 800 +cancer cell lines (including some proprietary to ChemPartner )
- 100+ cell-based assays for profiling phenotypes, oncogenic signaling and cell metabolism, along with the capacity for both high throughput and high content cell-based drug screening
- 200 +cell line-derived tumor xenograft (CDX )models
- Approximately 270 patient-derived xenograft (PDX )models that are coupled with genetic annotations
- Syngeneic tumor models and combination studies with immunotherapies
- Additional services in in vivo target validation, in vivo imaging, tumor-infiltrated immune cell profiling (TIL analysis), and tumor metabolite evaluation to in situ detection of copy number variance(FISH) or gene expression changes (RNA-ISH)
Working together with our clients, thousands of oncology drug discovery studies have been conducted, among which many are now in clinical trials or having been apprvoed by FDA for clinical use.
At ChemPartner, we believe in being at the cutting edge of science which is why we never stop building our expertise in new technologies and emerging new research areas such as Cancer Metabolism, Epigenetics and Immuno-oncology. We are committed to delivering the highest quality science and the very best customer experience. Together we can and will make a difference in science, and in cancer patients’ lives.
Anti-tumor efficacy study in subcutaneous, orthotopic, and systemic models
Once a compound showed efficacy in vitro, it can be transferred to our in vivo team to test its in vivo efficacy. In vivo PK study and Maximal Tolerance Dose (MTD) determination are often needed prior to the in vivo efficacy test. Depending on targets and mechanisms, the in vivo efficacy will be conducted in xenograft models (CDX/PDX) or syngeneic models (Immuno-oncology related). The readouts will be tumor volume, body weight, clinical signs, tumor weight and tumor pictures at the study termination, or overall survival.
PK/PD study in tumor bearing animal
It is important to obtain the compound’s PKPD profile to understand the correlation between compound exposure and target engagement/PD effect, so to better understand and improve efficacy. PK/PD study is often done using tumor-bearing mice, with drug concentrations being quantified by LC/MS, and PD effect being assessed by Western blot, qPCR, FACS, ELISA, LC/MS/MS, and IHC, etc.
New model development
ChemPartner has more than 200 established cell line derived xenogtraft (CDX) models and more than 270 patient-derived xenograft (PDX) models, including subcutaneous, orthotopic and systemic models. In addition to our established models, we can also develop new xenograft models for our clients within 8-10 weeks for CDX or 4-6 months for PDX models.